SynthesisScientific reports2016
Factors influencing immunologic response to hepatitis B vaccine in adults.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- A systematic review reveals that African children of 15-17 years demonstrate low hepatitis B vaccine seroprotection rates.Scientific reports · 2023Pooled it
- Suitable hepatitis B vaccine for adult immunization in China: a systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2019Pooled it
- Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China.Human vaccines & immunotherapeutics · 2025Trial
- Vaccination Schedule and Age Influence Impaired Responsiveness to Hepatitis B Vaccination: A Randomized Trial in Central Asia.Pathogens (Basel, Switzerland) · 2024Trial
- Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.Journal of viral hepatitis · 2019Trial
- Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody.AIDS research and therapy · 2019Trial
- Systemic Inflammation and the Persistence of Vaccine-Induced Hepatitis B Immunity in Healthcare Workers.Medical science monitor : international medical journal of experimental and clinical research · 2026Observational
- Hepatitis B Virus: Epidemiology, Prophylaxis, Therapy, Clinical Outcomes, and Novel Therapeutic Directions.Biomolecules · 2026Review
- Lymphoid-Tissue-on-Chip Recapitulates Human Antibody Responses In Vitro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine.Vaccines · 2026Review
- Seroprotection after a Standard Three-Dose Hepatitis B Vaccination Series in Immune-Mediated Rheumatic Diseases: A Retrospective Observational Study.Infectious diseases & clinical microbiology · 2026Article
- Hepatitis B Virus, Pneumococcal, Diphtheria, and Tetanus Vaccination Responses in Compensated Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- National trends in acute viral hepatitis in China from 1990-2023: An analysis of the Global Burden of Disease 2023 update.Chinese medical journal · 2026Article
- Article
- Hepatitis B Vaccine Response in Children of Vaccinated Versus Unvaccinated Mothers: A Retrospective Cohort Study.Journal of viral hepatitis · 2026Article
- Immunometabolic determinants of hepatitis B vaccine seroprotection among Ethiopian adults.Scientific reports · 2026Article
- Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment.International journal of molecular sciences · 2026Observational
- Factors Associated with the Anamnestic Immune Response Following Hepatitis B Booster Vaccination in the Elderly.Vaccines · 2026Article
- Occult hepatitis B virus infection among hepatitis B surface antigen negative vaccinated healthcare workers in East Gojjam zone hospitals.Scientific reports · 2026Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age ≥ 40) (RR:1.86, 95% CI:1.55-2.23), male adults (RR:1.40, 95% CI:1.22-1.61), BMI ≥ 25 adults (RR:1.56, 95% CI:1.12-2.17), smoker (RR:1.53, 95% CI:1.21-1.93), and adults with concomitant disease (RR:1.39, 95% CI:1.04-1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age ≥ 30) (RR:1.77, 95% CI:1.48-2.10), and adults (age ≥ 60) (RR:1.30, 95% CI:1.01-1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR:0.90, 95% CI:0.64-1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR:1.39, 95% CI:0.41-4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI ≥ 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.